



05/30/02

DOCKET NO.: A073US CON

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Philip Gotwals, et al

Application No.: 10/061,658

Group Art Unit: 1644

Filed: 01 February 2002

Examiner: To Be Assigned

Title: METHOD FOR THE TREATMENT OF FIBROSIS

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Post Office as First Class Mail addressed to Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: 30 May 2002

Signature: Jessie K Myers

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

☐ under 37 CFR 1.97(c) together with either:

☐ a Statement under 37 CFR 1.97(e), as checked below, or

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:

☐ a Statement under 37 CFR 1.97(e), as checked below, and

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

☐ under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
 - ☐ Copies of the cited references are enclosed.
 - ☒ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. 09/557,092, to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
 - ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
 - ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
 - ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ the enclosed English language abstract.

☐ Applicant requests that the following non-published pending applications be considered:

Examiner's
Initials

_____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
_____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
_____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 02-2327 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 02-2327.

Respectfully submitted,

BIOGEN, INC.

By

John T. Li

Registration No.: 44,210

Telephone: (617) 679-0200

Facsimile: (617) 679-2838

Cambridge, MA 02142

Dated: 5-30-02

#10481

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

A073 U.

Application Number

10/061,658

Applicant(s)

Phillip Gotwals et al.

Filing Date

01 FEBRUARY 2002

Group Art Unit

1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,798,230	8/25/98	Bornkamm et al.			4/3/96
	AB	5,789,650	8/4/98	Lonberg et al.			3/18/92
	AC	4,683,195	7/28/87	Mullis et al.			2/7/86

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
	BA	WO 90/07861	7/26/90					
	BB	EP 0239400 B1	9/30/97					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	Baldwin et al., 1998, Structure, 6:923-935, "Cation binding to the integrin CD11b I domain and activation model assessment"
	CB	Bennett et al., 1983, Proc. Natl. Acad. Sci., 80:2417-2421, "Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody"

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

A073 U

ON

Application Number

10/061,658

Applicant(s)

Philip Gotwals et al.

Filing Date

01 FEBRUARY 2002

Group Art Unit

1644

*EXAMINER

INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Boerner et al., 1991, J. Immunol., 147:86-95, "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes"

Border et al., 1994, New England J. Medicine, 331:1286-1292, "Transforming Growth Factor Beta In Tissue Fibrosis"

Bossy et al., 1991, EMBO J., 10:2375-2385, "Characterization of the Integrin Alpha8 subunit: A new integrin beta1-associated subunit, which is prominently expressed on axons and on cells in contact with basal laminae in chick embryos"

Briesewitz et al., 1993, J. of Biol. Chemistry, 268:2989-2996, "Expression of Native and Truncated Forms of the human integrin Alpha1 1 subunit"

Bridges et al., 1995, Mol. Immunol., 32:1329-2989, "Variable Region cDNA Sequences and Characterization of Murine Anti-Human Interferon gamma Receptor Monoclonal Antibodies that Inhibit Receptor Binding By Interferon gamma"

Camper et al., 1998, J. Biol. Chem., 273:20383-20389, "Isolation, Cloning, and Sequence Analysis of the Integrin Subunit alpha10, a Beta1-associated Collagen Binding Integrin Expressed on Chondrocytes"

Cerf-Bensussan et al., 1992, Eur. J. Immunol. 22:273-277, "The human intraepithelial lymphocyte marker HML-1 is an integrin consisting of a Beta7 subunit associated with a distinctive alpha chain"

Clackson et al., 1991, Nature, 352:624-628, "Making antibody fragments using phage display libraries"

Co et al., 1991, Proc. Natl Acad. Sci., 88:2869-2873, "Humanized antibodies for antiviral therapy"

Colbert et al, 1991, J. of Immunol. Methods, 140: 227-233, "The effect of fluorescein labels on the affinity of antisera to small haptens"

Corbi and Miller et al., 1987, J. of Biol. Chem., 263: 12403-12411, "cDNA cloning and complete primary structure for the alpha subunit of a leukocyte adhesion glycoprotein, p150,95"

Corbi and Kishimoto et al., 1988, J. of Biol. Chem., 263: 12403-12411, "The Human Leukocyte Adhesion Glycoprotein Mac-1 (Complement Receptor Type 3, CD11b) alpha Subunit"

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

A073 U.

Application Number

10/061,658

Applicant(s)

Philip Gotwals et al.

Filing Date

01 FEBRUARY 2002

Group Art Unit

1644

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Davies, 1989, J. of Cell Biology, 109: 1817-1826, "The Osteoclast Functional Antigen, Implicated in the Regulation of Bone Resorption, Is Biochemically Related to the Vitronectin Receptor"

Diamond et al., 1993, 120: 1031-1043, "The I Domain Is a Major Recognition Site on the Leukocyte Integrin Mac-1 (CD-11b/CD18) For Four Distinct Adhesion Ligands"

Edwards et al., 1995, 270:12635-12640, "Identification of Amino Acids in the CD11a I-domain Important for Binding of the Leukocyte Function-associated Antigen-1 (LFA-1) to Intercellular Adhesion Molecules-1 (ICAM-1)*"

Gotwals et al., 1996, J. Clin. Invest., 97:2469-2477, "The $\alpha 1 \beta 1$ Integrin is expressed during Neointima Formation in Rat Arteries and Mediates Collagen Matrix Reorganization"

Grayson et al., 1998, J. Exp. Med., 188:2187-2191, "alpha2beta2 Integrin Is Expressed on Human Eosinophils and Functions as an Alternative Ligand for Vascular Cell Adhesion Molecule 1 (VCAM-1)"

Hemler et al., 1984, J. of Immunol., 132:3011-3018, "Glycoproteins of 210,000 and 130,000 M.W. On Activated T Cells: Cell Distribution And Antigenic Relation To Components On Resting Cells And T Cell Lines"

Hemler et al., 1987, J. of Immunol., 262:11478-11485, "Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides"

Hessle et al., 1984, Differentiation, 26:49-54, "Basement membrane diversity detected by monoclonal antibodies"

Ignatius et al., 1990, J. of Cell Biology, 111:709-720, "Molecular Cloning of the Rat Integrin alpha1 Subunit: A Receptor for Laminin and Collagen"

Kamata et al., 1995, J. of Biological Chem., 270:12531-12535, "Critical Threonine and Aspartic Acid Residues within the I Domains of beta2 Integrins for Interactions with Intercellular Adhesion Molecule 1 (ICAM-1) and C3bi*"

Keely et al., 1995, J. of Cell Science, 108:595-607, "Alteration of collagen-dependent adhesion, motility, and morphogenesis by the expression of antisense alpha2 integrin mRNA in mammary cells"

Kern et al., 1994, J. of Biol. Chem., 269:22811-55816, "The Role of the I Domain in Ligand Binding of the Human Integrin alpha1beta1"

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

A073 U

Application Number

10/061,658

Applicant(s)

Phillip Gotwal et al.

Filing Date


01 FEBRUARY 2002

Group Art Unit

1644

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)



Langholz et al., 1995, J. of Cell Biol., 131:1903-1915, "Collagen and Collagenase Gene Expression in Three-dimensional Collagen Lattices Are Differentially Regulated by alpha1beta1 and alpha2beta1 Integrins"

Larson et al., 1989, J. of Cell Biol., 108:703-712, "Primary Structure of the Leukocyte Function-associated Molecule-1 alpha Subunit: an Integrin with an Embedded Domain Defining a Protein Superfamily"

Lee et al., 1995, Structure, 3:1333-1340, "Two conformations of the integrin A-domain (I-domain): a pathway for activation?"

Lowry et al., 1951, Dept. of Pharma., Washington Univ. School of Med., 265-275, "Protein Measurement with the folin phenol reagent"

Mendrick et al., 1995, Laboratory Investigation, 72:367-375, "Glomerular Epithelial and Mesangial Cells Differentially Modulate the Binding Specificities of VLA-1 and VLA-2"

Michishita et al., 1993, Cell Press, 72:857-867, "A Novel Divalent Cation-Binding Site in the A Domain of the Beta2 Integrin CR3 (CD11b/CD18) Is Essential for Ligand Binding"

Nagler et al., 1996, Am. J. Respir. Crit. Care Med., 154:1082-1086, "Reduction in Pulmonary Fibrosis *In Vivo* by Halofuginone"

Nishimura et al., 1994, J. of Biol. Chem., 269:28708-28715, "Integrin- α vBeta8"

Orlandi, 1989, Proc. Natl. Acad. Sci., 86:3833-3837, "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction"

Persson et al., 1991, Proc. Natl. Acad. Sci., 88:2432-2436, "Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning"

Pischel et al., 1987, J. of Immunol., 138:226-233, "Use of the monoclonal antibody 12F1 to Characterize the Differentiation Antigen VLA-21"

Qu et al., 1995, Proc. Natl. Acad. Sci., 92:10277-10281, "Crystal structure of the I-domain form the CD11a/CD18 (LFA-1, α Lbeta2) integrin"

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)

A073 I

ON

Application Number

10/061,658

Applicant(s)

Philip Gotwals et al.

Filing Date

01 FEBRUARY 2002

Group Art Unit

1644

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Qu et al., 1996, Structure, 4:931-942, "The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin"

Queen et al., 1989, Proc. Natl. Acad. Sci., 86:10029-10033, "A humanized antibody that binds to the interleukin 2 receptor"

Riechmann et al., 1988, Nature, 332:323-327, "Reshaping human antibodies for therapy"

Riikonen et al., 1994, J. of Biol. Chem., 270:376-382, "Transforming Growth Factor-beta Regulates Collagen Gel..."

Sanchez-Madrid et al., 1982, Immunol., 79:7489-7493, "Three distinct antigens associated with human T-lymphocyte-mediated cytotoxicity..."

Schiro et al., 1991, Cell, 67:403-410, "Integrin alpha2beta1 (Iv1a-2) Mediates Reorganization and Contraction of Collagen Matrices by Human Cells"

Shaw et al., 1994, J. of Biol. Chem., 269:6016-6025, "Molecular Cloning of the Human Mucosal Lymphocyte Integrin α Subunit"

Sonnenberg et al., 1987, J. of Biol. Chem., 262:10376-10383, "A Complex of Platelet Glycoproteins Ic and IIa Identified by a Rat Monoclonal Antibody"

Springer et al., 1990, Nature, 346:425-434, "Adhesion receptors of the immune system"

Stacker et al., 1991, J. of Immunol., 146:648-655, "Leukocyte Integrin P150,95 (CD11c/CD18) Functions..."

Takada et al., 1989, J. of Cell Biol., 109:397-407, "The Primary Structure of the VLA-2/Collagen Receptor α 2 Subunit"

Tempest et al., 1991, Bio/Tech., 9:266-271, "Reshaping A Human Monoclonal Antibody TO Inhibit Human Respiratory Syncytial Virus Infection *In Vivo*"

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

A073

CON

Application Number

10/061,658

Applicant(s)

Phillip Gotwals et al.

Filing Date

01 FEBRUARY 2002

Group Art Unit

1644

*EXAMINER

INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DY

Van der Vieren et al., 1995, Immunity, 3:683-690, "A Novel Leukointegrin, *alphadbeta2*, Binds Preferentially to ICAM-3"

DZ

Verhoeven et al., 1987, Science, 239:1534-1536, "Reshaping Human Antibodies: Grafting an Antilysozyme Activity"

EA

Wang et al., 1996, Am. J. Respir. Cell Mol. Biol., 15:664-672, "Differential Regulation of Airway Epithelial Integrins..."

EB

Ward et al., 1989, Nature, 341:544-546, "Binding activities of a repertoire of single immunoglobulin variable domains..."

EC

Wayner et al., 1988, "J. of Cell Biol., 107:1881-1891, "The Function of Multiple Extracellular Matrix Receptors..."

ED

Weinacker et al., 1993, J. of Biol. Chem., 269:6940-6948, "Role of the Integrin *alphavbeta6* in Cell Attachment to Fibronectin"

EE

Woessner et al., 1961, Arch. of Biochem. and Biophys., 93:440-447, "The Determination of Hydroxyproline in Tissue..."

EF

Yao et al., 1996, J. of Cell Science, 109:3139-3150, "Laminins promote the locomotion of skeletal myoblasts..."

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Gotwals, et al.
Application No.: 10/061,658
Filed: February 1, 2002
Page 1 of 2

Docket No. A073 USCont




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gotwals, et al.
Application No.: 10/061,658 Group Art Unit: 1644
Filed: February 1, 2002 Examiner: Maher Haddad Ph.D.
Title: METHOD FOR THE TREATMENT OF FIBROSIS

EU557136640US
EXPRESS MAIL NO. A:

DEPOSITED: May 1, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service Express Mail under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, MS Patent Application.



Kevin J. McGough

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT

Sir:

This Supplementary Information Disclosure Statement is submitted pursuant to 37 C.F.R. § 1.97(d).

Claims 1-8 are pending in this application and are under examination. Claims 1-8 have been rejected. On March 3, 2003, Applicants submitted a response to the non-final October 2, 2002 Office Action issued by the Examiner in connection with this application.

REMARKS

A copy of a February 26, 2003 Associate Power of Attorney in the instant application that was granted to Kevin J. McGough by an attorney of record for the Applicants was submitted on March 3, 2003. Authorization was given, and the Patent and Trademark Office is hereby requested, to charge Biogen Deposit Account 02-2327 for all fees required in connection with the filing of the instant Supplementary Information Disclosure Statement. If, for whatever reason, the Patent and Trademark Office will not charge those fees to Biogen Deposit Account 02-2327, authorization is hereby given to charge the fees in the alternative to Coleman, Sudol & Sapone Deposit Account 04-0838.

Applicants have respectfully requested that future communications in connection with the instant application be addressed to Mr. McGough care of Coleman, Sudol & Sapone at the address provided below. Mr. McGough's office phone number is 914-337-4082.

This Supplementary Information Disclosure Statement is being submitted to make of record references cited in connection with the prosecution of a related PCT/European Patent Application. This Supplementary Information Disclosure Statement is being submitted together with: (1) a PTO form 1449 listing the references; (2) copies of the references.

Applicants: Gotwals, et al.
Application No.: 10/061,658
Filed: February 1, 2002
Page 3 of 3

Docket No. A073 USCont

The Examiner is requested to return a copy of the attached PTO form 1449 with the next Office Action or Notice of Allowance and is requested to indicate on that copy those of the listed references which he considered. It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,



Kevin J. McGough

Reg. No. 31,279

Attorney for the Applicants

914-337-4082 (Office Number)

Of Counsel-Coleman, Sudol & Sapon
714 Colorado Avenue
Bridgeport, CT 06605-1601
(203) 366-3560
Date: May 1, 2003



Approved for use through 04/30/2003 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 949/PTO

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/061,658
Filing Date	February 1, 2002
First Named Inventor	Gotwals, et al.
Art Unit	1644
Examiner Name	Maher Hadded, Ph. D.
Attorney Docket Number	Biogen A073USCont

U. S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)	MM-DD-YYYY			
		WO97 18838	5/29/97			
		WO97 11718	4/3/97			
		WO9313798	7/22/93			
		WO95 19790	7/27/95			
		WO94 17828	9/18/94			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Compl t if Kn wn	
		Applicati n Numb r	10/061,658
		Filing Date	February 1, 2002
		First Named Inventor	Gotwals, et al.
		Art Unit	1644
		Examiner Name	Maher Haddad, Ph. D.
Sheet 2	of 2	Attorney Docket Number	BiogenA073USCont

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EG	Pappadopoulos, et al; Verh. Dtsch. Ges. Path. 77, 292-295 (1993)(Germany)	
	EH	Hokibara, et al., Cln Exp Immunol. 1998: 114: 236-44(United Kingdom)	
	EI	Roy-Chaudhury, et al., Kidney International, Vol. 49 (1996); pp. 127-134(US)	
	EJ	Lin, et al., Current Opinign in chemical Biology, vol. 2, no. 4, August 1998 (1998-08), pp. 453-457 (UNITED KINGDOM)	
	EK	Robb, et al., Journal of Clinical Investigation, vol. 94, no. 5, Nov. 1994 (1994-11), pp. 1722-1728 (US)	
	EL	Robb, et al. European Respiratory Journal, Supplement, vol. 9, no. supp. 22, August 1996 (1996-08) (DEUTSCH)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.